Text Size

Safety and Efficacy of a Novel Topical Therapy for Tinea Pedis (Athlete's Foot)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2009 by Hillel Yaffe Medical Center.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier:
NCT00848666
First received: August 28, 2008
Last updated: February 23, 2009
Last verified: February 2009
History of Changes
  Purpose

The purpose of this study is to evaluate the safety and efficacy of a novel topical therapy in patients with laboratory confirmed tinea pedis. During the follow-up period clinical and mycological examinations will be performed.


Condition Intervention
Tinea Pedis
 Drug: Topical therapy

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Hillel Yaffe Medical Center:

Primary Outcome Measures:
  • Cure of tinea pedis [ Time Frame: One year ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 100
Study Start Date: April 2009
Estimated Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: I
Patients with tinea pedis
 Drug: Topical therapy
One time immersion of the feet in a liquid containing water, alcohol, vinegar, benzoic acid and salicylic acid for a total of 30 minutes.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Otherwise healthy patients with laboratory proven tinea pedis

Exclusion Criteria:

  • Age lower than 18 and higher than 80
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00848666

Locations
Israel
Hillel Yaffe Medical Center Not yet recruiting
Hadera, Israel, 38100
Contact: Kahana     972-4-6304667     kahanam@hy.health.gov.il    
Principal Investigator: Michael Kahana, MD            
Sponsors and Collaborators
Hillel Yaffe Medical Center
  More Information

No publications provided

Responsible Party: Dr. Michael Kahana, Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier: NCT00848666     History of Changes
Other Study ID Numbers: HYMC 48-08
Study First Received: August 28, 2008
Last Updated: February 23, 2009
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Tinea Pedis
Tinea
Dermatomycoses
Skin Diseases, Infectious
Infection
Mycoses
 Skin Diseases
Foot Dermatoses
Foot Diseases
Pruritus
Skin Manifestations
Signs and Symptoms

ClinicalTrials.gov processed this record on May 16, 2013